H2-antagonists in the treatment of colon and breast cancer

Several clinical trials have now been carried out with histamine type 2 rec eptor antagonists in cancer patients often as an adjunct to surgical resect ion of the primary tumour. While promising results have been obtained in so me groups of patients with gastrointestinal cancer, with increased survival and evidence of increased immunological recognition of tumour; results are less encouraging for breast cancer This may be due to differences in the l evels of histamine or the role of histamine in growth of these different tu mour types.